Randomized trial · people

Abaloparatide then alendronate: 84% lower vertebral fracture risk

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In postmenopausal women, 18 months of abaloparatide followed by alendronate kept fracture risk lower and kept building bone density compared with alendronate after placebo.

Kind
Randomized trial
Studied in
People
Published
2018
Journal
J Clin Endocrinol Metab

What they tested

The team tested whether 24 months of alendronate after 18 months of abaloparatide lowers fracture risk and builds bone density more than alendronate after 18 months of placebo in postmenopausal women with osteoporosis.

How the study was done

A follow-on to the placebo-controlled ACTIVE trial. Women who finished ACTIVE on abaloparatide or placebo could take up to 24 months of alendronate, and 92% of those completers enrolled. Fractures and bone mineral density (BMD, a measure of bone strength on a scan) were tracked across the full 43 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Across the full 43 months, 0.9% of women in the abaloparatide-then-alendronate group had a new vertebral (spine) fracture on X-ray, vs 5.6% in the placebo-then-alendronate group. That is an 84% relative risk reduction (P < 0.001). Rates of the other fracture types were also lower in the abaloparatide group (all P < 0.05), BMD gains from the first 18 months kept rising during the alendronate phase, and in the alendronate phase alone vertebral fracture risk was 87% lower (P = 0.001). A separate analysis found no hip fractures in the abaloparatide group while the placebo group had some, and side effects were similar between groups.

What it doesn’t show

Only women who finished the first trial joined, and the study compared two sequences rather than abaloparatide against alendronate alone. All participants were postmenopausal women, so it does not speak to men or other groups.

The paper

Bone et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018.

The compound

More studies on Abaloparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo